Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSESS: Aflibercept in previously treated exudative AMD
NCT01617148Phase 4Completed
- Sponsor
- Rishi Singh
- Start
- Jun 2012
- Primary completion
- Dec 2013
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative age-related macular degeneration, sponsored by Rishi Singh. Primary endpoint: Change in Central Subfield Thickness From Baseline at 12 months. Started Jun 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT01617148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01617148.